Supplementary Figure S1: Overall pooling in analyzed studies showing 12-month changes in visual acuity. Forest plot.

| Study name | Subgroup within study | Year | Study design | Study type | Drug class | Drug | Regimen | Statistics for each study | | | | | | | | Weight (Random) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Difference in means | Standard error | Variance | Lower limit | Upper limit | Z-Value | p-Value | Total | Relative weight | Std Residual |
| Talks et al. | Ranibizumab 0,5 mg | 2019 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 4,100 | 32,235 | 1039,110 | -59,080 | 67,280 | 0,127 | 0,899 | 22 | 0,02 | -0,12 |
| Payne et al. (B) | Ranibizumab 0,3 mg | 2016 | Prospective | Large RCT | AntiVEGF | Ranibizumab | TAE | 9,600 | 37,695 | 1420,946 | -64,282 | 83,482 | 0,255 | 0,799 | 52 | 0,01 | 0,04 |
| Payne et al. (A) | Ranibizumab 0,3 mg | 2016 | Prospective | Large RCT | AntiVEGF | Ranibizumab | FIX | 8,600 | 33,624 | 1130,593 | -57,302 | 74,502 | 0,256 | 0,798 | 29 | 0,02 | 0,01 |
| Malcles et al. | Dexamethasone implant (0,7 mg) | 2017 | Retrospective | Real-life/Observational | Steroid | Dex implant | PRN | 6,600 | 7,909 | 62,551 | -8,901 | 22,101 | 0,834 | 0,404 | 34 | 0,25 | -0,17 |
| Ozkaya et al. | Aflibercept 2 mg | 2019 | Retrospective | Real-life/Observational | AntiVEGF | Aflibercept | PRN | 11,600 | 5,632 | 31,723 | 0,561 | 22,639 | 2,060 | 0,039 | 26 | 0,40 | 0,50 |
| Ozkaya et al. | Dexamethasone implant (0,7 mg) | 2015 | Retrospective | Real-life/Observational | Steroid | Dex implant | PRN | 1,500 | 1,707 | 2,915 | -1,847 | 4,847 | 0,879 | 0,380 | 50 | 0,96 | -1,47 |
| Ozkaya et al. | Ranibizumab 0,5 mg | 2019 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 10,700 | 5,112 | 26,135 | 0,680 | 20,720 | 2,093 | 0,036 | 20 | 0,45 | 0,39 |
| Ozkaya et al. | Ranibizumab 0,5 mg - 2013 | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 1,000 | 2,162 | 4,673 | -3,237 | 5,237 | 0,463 | 0,644 | 53 | 0,89 | -1,52 |
| Ozkaya et al. | Ranibizumab 0,5 mg - 2014 | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 6,500 | 1,793 | 3,213 | 2,987 | 10,013 | 3,626 | 0,000 | 71 | 0,95 | -0,36 |
| Ozkaya et al. | Ranibizumab 0,5 mg - 2015 | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 7,500 | 1,578 | 2,491 | 4,407 | 10,593 | 4,752 | 0,000 | 49 | 0,98 | -0,14 |
| Yaseri et al. | Bevacizumab 1,25 mg | 2014 | Retrospective | Real-life/Observational | AntiVEGF | Bevacizumab | FIX | 15,000 | 4,837 | 23,394 | 5,520 | 24,480 | 3,101 | 0,002 | 8 | 0,48 | 1,08 |
| Pareja-Rios et al. | Dexamethasone implant (0,7 mg) | 2018 | Retrospective | Real-life/Observational | Steroid | Dex implant | PRN | 3,200 | 3,562 | 12,687 | -3,781 | 10,181 | 0,898 | 0,369 | 11 | 0,65 | -0,90 |
| Kriechbaum et al. | Bevacizumab 1,25 mg | 2013 | Prospective | Real-life/Observational | AntiVEGF | Bevacizumab | PRN | 6,000 | 3,236 | 10,473 | -0,343 | 12,343 | 1,854 | 0,064 | 30 | 0,70 | -0,40 |
| Borrelli et al. | Dexamethasone implant | 2019 | Retrospective | Real-life/Observational | Steroid | Dex implant | FIX | 6,500 | 3,220 | 10,367 | 0,189 | 12,811 | 2,019 | 0,044 | 6 | 0,71 | -0,31 |
| Karst et al. | Ranibizumab 0,5 mg | 2017 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 8,000 | 2,850 | 8,125 | 2,413 | 13,587 | 2,807 | 0,005 | 10 | 0,77 | -0,03 |
| Ghanchi et al. | Ranibizumab 0,5 mg | 2016 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 3,400 | 2,698 | 7,281 | -1,889 | 8,689 | 1,260 | 0,208 | 9 | 0,79 | -0,95 |
| Chhablani et al. | Dexamethasone implant (0,7 mg) | 2015 | Retrospective | Real-life/Observational | Steroid | Dex implant | PRN | 7,000 | 2,611 | 6,817 | 1,883 | 12,117 | 2,681 | 0,007 | 15 | 0,81 | -0,23 |
| Matonti et al. | Dexamethasone implant (0,7 mg) | 2016 | Retrospective | Real-life/Observational | Steroid | Dex implant | FIX | 8,700 | 2,597 | 6,743 | 3,611 | 13,789 | 3,350 | 0,001 | 23 | 0,81 | 0,12 |
| Brown et al. | Ranibizumab 0,3 mg | 2017 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 15,700 | 2,527 | 6,385 | 10,748 | 20,652 | 6,213 | 0,000 | 20 | 0,82 | 1,56 |
| Do et al. (DA VINCI) | Aflibercept 0.5q4 | 2012 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 11,000 | 2,498 | 6,241 | 6,104 | 15,896 | 4,403 | 0,000 | 38 | 0,83 | 0,59 |
| Do et al. (DA VINCI) | Aflibercept 2PRN | 2012 | Prospective | Large RCT | AntiVEGF | Aflibercept | PRN | 12,000 | 1,801 | 3,242 | 8,471 | 15,529 | 6,664 | 0,000 | 38 | 0,95 | 0,85 |
| Do et al. (DA VINCI) | Aflibercept 2q4 | 2012 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 13,100 | 1,828 | 3,341 | 9,518 | 16,682 | 7,167 | 0,000 | 33 | 0,94 | 1,09 |
| Do et al. (DA VINCI) | Aflibercept 2q8 | 2012 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 9,700 | 1,526 | 2,330 | 6,708 | 12,692 | 6,355 | 0,000 | 34 | 0,99 | 0,35 |
| Gillies et al. (BEVORDEX) | Bevacizumab 1,25 mg | 2014 | Prospective | Large RCT | AntiVEGF | Bevacizumab | PRN | 8,900 | 1,358 | 1,844 | 6,239 | 11,561 | 6,554 | 0,000 | 42 | 1,02 | 0,18 |
| Gillies et al. (BEVORDEX) | Dexamethasone implant (0,7 mg) | 2014 | Prospective | Large RCT | Steroid | Dex implant | PRN | 5,600 | 2,403 | 5,776 | 0,890 | 10,310 | 2,330 | 0,020 | 46 | 0,84 | -0,53 |
| Fouda et al. | Aflibercept 2 mg | 2017 | Prospective | Real-life/Observational | AntiVEGF | Aflibercept | PRN | 19,500 | 2,325 | 5,407 | 14,942 | 24,058 | 8,386 | 0,000 | 35 | 0,86 | 2,39 |
| Fouda et al. | Ranibizumab 0,5 mg | 2017 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 15,500 | 2,197 | 4,829 | 11,193 | 19,807 | 7,054 | 0,000 | 35 | 0,88 | 1,57 |
| Georgios et al. | Bevacizumab 1,25 mg | 2020 | Prospective | Real-life/Observational | AntiVEGF | Bevacizumab | FIX | 6,000 | 2,312 | 5,347 | 1,468 | 10,532 | 2,595 | 0,009 | 15 | 0,86 | -0,45 |
| Mylonas et al. | Bevacizumab 2,5 mg | 2020 | Prospective | Real-life/Observational | AntiVEGF | Bevacizumab | FIX | 6,000 | 2,312 | 5,347 | 1,468 | 10,532 | 2,595 | 0,009 | 15 | 0,86 | -0,45 |
| Bagel-Bernaldiz et al. | Ranibizumab 0,5 mg | 2017 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 12,400 | 2,207 | 4,872 | 8,074 | 16,726 | 5,618 | 0,000 | 35 | 0,88 | 0,91 |
| Menezo et al. | Dexamethasone implant (0,7 mg) | 2019 | Prospective | Real-life/Observational | Steroid | Dex implant | PRN | 8,200 | 2,166 | 4,690 | 3,955 | 12,445 | 3,786 | 0,000 | 50 | 0,89 | 0,01 |
| Nepomuceno et al. | Bevacizumab 1,25 mg | 2013 | Prospective | Real-life/Observational | AntiVEGF | Bevacizumab | PRN | 12,000 | 1,917 | 3,675 | 8,243 | 15,757 | 6,260 | 0,000 | 32 | 0,93 | 0,84 |
| Nepomuceno et al. | Ranibizumab 0,5 mg | 2013 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 14,500 | 2,163 | 4,680 | 10,260 | 18,740 | 6,702 | 0,000 | 28 | 0,89 | 1,36 |
| Jabbarpoor Bonyadi et al. | Bevacizumab 1,25 mg | 2017 | Prospective | Real-life/Observational | AntiVEGF | Bevacizumab | FIX | 13,500 | 2,140 | 4,578 | 9,306 | 17,694 | 6,310 | 0,000 | 39 | 0,89 | 1,15 |
| Campos Polo et al. | Aflibercept 2 mg | 2018 | Prospective | Real-life/Observational | AntiVEGF | Aflibercept | FIX | 14,900 | 2,015 | 4,060 | 10,951 | 18,849 | 7,395 | 0,000 | 29 | 0,91 | 1,46 |
| Abouhussein et al. | Aflibercept 2 mg | 2020 | Prospective | Real-life/Observational | AntiVEGF | Aflibercept | PRN | 23,000 | 2,002 | 4,010 | 19,075 | 26,925 | 11,486 | 0,000 | 20 | 0,91 | 3,22 |
| Tsai et al. | Ranibizumab 0,5 mg | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 4,900 | 1,988 | 3,951 | 1,004 | 8,796 | 2,465 | 0,014 | 39 | 0,92 | -0,70 |
| Chen et al. | Ranibizumab 0,5 mg | 2019 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 32,000 | 1,884 | 3,550 | 28,307 | 35,693 | 16,984 | 0,000 | 55 | 0,93 | 5,23 |
| Mahapatra et al. | Dexamethasone implant (0,7 mg) | 2020 | Prospective | Real-life/Observational | Steroid | Dex implant | Blank | 7,900 | 1,826 | 3,333 | 4,322 | 11,478 | 4,327 | 0,000 | 30 | 0,94 | -0,05 |
| Pak et al. | Aflibercept 2 mg | 2020 | Prospective | Real-life/Observational | AntiVEGF | Aflibercept | TAE | 9,100 | 1,821 | 3,316 | 5,531 | 12,669 | 4,997 | 0,000 | 46 | 0,94 | 0,21 |
| Prager et al. | Ranibizumab 0,5 mg | 2017 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 8,000 | 1,803 | 3,250 | 4,467 | 11,533 | 4,438 | 0,000 | 25 | 0,95 | -0,03 |
| Takasago et al. | Ranibizumab 0,5 mg | 2019 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 4,500 | 1,768 | 3,125 | 1,035 | 7,965 | 2,546 | 0,011 | 30 | 0,95 | -0,80 |
| Nguyen et al. (READ-2) | Ranibizumab 0,5 mg | 2010 | Prospective | Large RCT | AntiVEGF | Ranibizumab | PRN | 7,000 | 1,624 | 2,639 | 3,816 | 10,184 | 4,309 | 0,000 | 42 | 0,98 | -0,25 |
| Schwarzer et al. | Aflibercept 2 mg | 2019 | Prospective | Real-life/Observational | AntiVEGF | Aflibercept | TAE | 6,800 | 1,542 | 2,377 | 3,778 | 9,822 | 4,410 | 0,000 | 30 | 0,99 | -0,30 |
| Schwarzer et al. | Ranibizumab 0,5 mg | 2019 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | TAE | 6,300 | 1,340 | 1,796 | 3,673 | 8,927 | 4,701 | 0,000 | 25 | 1,02 | -0,42 |
| Pareja-Rios et al. | Dexamethasone implant (0,7 mg) | 2018 | Retrospective | Real-life/Observational | Steroid | Dex implant | FIX | 4,200 | 1,453 | 2,112 | 1,352 | 7,048 | 2,890 | 0,004 | 113 | 1,00 | -0,89 |
| Yule Xu et al. | Ranibizumab 0,5 mg | 2017 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 8,900 | 1,419 | 2,015 | 6,118 | 11,682 | 6,270 | 0,000 | 32 | 1,01 | 0,18 |
| Sato et al. | Ranibizumab 0,5 mg | 2017 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 2,000 | 1,406 | 1,976 | -0,755 | 4,755 | 1,423 | 0,155 | 56 | 1,01 | -1,40 |
| Korobelnik et al. | Aflibercept 2 mg | 2019 | Prospective | Real-life/Observational | AntiVEGF | Aflibercept | FIX | 7,800 | 1,402 | 1,965 | 5,053 | 10,547 | 5,565 | 0,000 | 77 | 1,01 | -0,08 |
| Khattab et al. | Aflibercelt 2 mg | 2019 | Prospective | Real-life/Observational | AntiVEGF | Aflibercept | PRN | 15,900 | 1,372 | 1,882 | 13,211 | 18,589 | 11,590 | 0,000 | 27 | 1,01 | 1,77 |
| Curry et al. | Aflibercept 2 mg | 2019 | Prospective | Real-life/Observational | AntiVEGF | Aflibercept | TAE | 4,600 | 1,345 | 1,808 | 1,964 | 7,236 | 3,421 | 0,001 | 25 | 1,02 | -0,81 |
| Hirarat et al. | Ranibizumab 0,5 mg | 2016 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 10,700 | 1,342 | 1,801 | 8,069 | 13,331 | 7,972 | 0,000 | 106 | 1,02 | 0,59 |
| Maggio et al. | Dexamethasone implant (0,7 mg) | 2018 | Retrospective | Real-life/Observational | Steroid | Dex implant | PRN | 5,000 | 1,255 | 1,574 | 2,541 | 7,459 | 3,985 | 0,000 | 170 | 1,03 | -0,72 |
| Kern et al. | Aflibercept 2 mg | 2020 | Retrospective | Real-life/Observational | AntiVEGF | Aflibercept | PRN | 4,800 | 1,242 | 1,542 | 2,366 | 7,234 | 3,866 | 0,000 | 91 | 1,03 | -0,77 |
| Tso-Ting Lai et a. | Ranibizumab 0,5 mg | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 5,000 | 1,226 | 1,502 | 2,598 | 7,402 | 4,080 | 0,000 | 119 | 1,03 | -0,72 |
| Michaelides et al. (BOLT Study) | Bevacizumab 1,25 mg | 2010 | Prospective | Real-life/Observational | AntiVEGF | Bevacizumab | PRN | 5,600 | 1,205 | 1,453 | 3,238 | 7,962 | 4,646 | 0,000 | 42 | 1,04 | -0,58 |
| Epstein et al. | Ranibizumab 0,5 mg | 2017 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 6,000 | 1,143 | 1,306 | 3,760 | 8,240 | 5,251 | 0,000 | 102 | 1,05 | -0,49 |
| Koc et al. | Bevacizumab 1,25 mg | 2017 | Retrospective | Real-life/Observational | AntiVEGF | Bevacizumab | PRN | 4,100 | 1,022 | 1,045 | 2,096 | 6,104 | 4,010 | 0,000 | 90 | 1,06 | -0,94 |
| Koc et al. | Ranibizumab 0,5 mg | 2017 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 5,400 | 1,015 | 1,030 | 3,411 | 7,389 | 5,321 | 0,000 | 101 | 1,06 | -0,64 |
| Chen et al. | Aflibercept 2q4 | 2020 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 13,600 | 0,900 | 0,810 | 11,836 | 15,364 | 15,112 | 0,000 | 122 | 1,07 | 1,29 |
| Chen et al. | Aflibercept 2q8 | 2020 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 13,100 | 1,000 | 1,000 | 11,140 | 15,060 | 13,100 | 0,000 | 116 | 1,06 | 1,16 |
| Patrao et al. | Ranibizumab 0,5 mg | 2016 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 6,600 | 0,944 | 0,891 | 4,750 | 8,450 | 6,992 | 0,000 | 200 | 1,07 | -0,36 |
| Berger et al. | Ranibizumab 0,5 mg | 2015 | Prospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 8,900 | 0,938 | 0,879 | 7,062 | 10,738 | 9,492 | 0,000 | 75 | 1,07 | 0,18 |
| Bhandari et al. (2) | Aflibercept 2,0 mg | 2019 | Retrospective | Large RCT | AntiVEGF | Aflibercept | PRN | 6,100 | 0,815 | 0,664 | 4,503 | 7,697 | 7,488 | 0,000 | 217 | 1,08 | -0,48 |
| Bhandari et al. (2) | Ranibizumab 0,5 mg | 2019 | Retrospective | Large RCT | AntiVEGF | Ranibizumab | PRN | 3,300 | 0,890 | 0,793 | 1,555 | 5,045 | 3,707 | 0,000 | 166 | 1,07 | -1,14 |
| Korobelnik et al. (VIVID) | Aflibercept 2q4 | 2014 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 10,500 | 0,850 | 0,722 | 8,835 | 12,165 | 12,357 | 0,000 | 125 | 1,08 | 0,56 |
| Korobelnik et al. (VIVID) | Aflibercept 2q8 | 2014 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 10,700 | 0,845 | 0,715 | 9,043 | 12,357 | 12,656 | 0,000 | 121 | 1,08 | 0,61 |
| James et al. | Ranibizumab 0,5 mg | 2019 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 6,000 | 0,829 | 0,688 | 4,375 | 7,625 | 7,236 | 0,000 | 180 | 1,08 | -0,50 |
| Prünte et al. (B) | Ranibizumab 0,5 mg | 2015 | Prospective | Large RCT | AntiVEGF | Ranibizumab | PRN | 7,440 | 0,791 | 0,626 | 5,889 | 8,991 | 9,401 | 0,000 | 117 | 1,08 | -0,16 |
| Korobelnik et al. (VISTA) | Aflibercept 2q4 | 2014 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 12,500 | 0,786 | 0,618 | 10,959 | 14,041 | 15,899 | 0,000 | 146 | 1,08 | 1,03 |
| Korobelnik et al. (VISTA) | Aflibercept 2q8 | 2014 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 10,700 | 0,683 | 0,467 | 9,361 | 12,039 | 15,659 | 0,000 | 144 | 1,09 | 0,61 |
| Prünte et al. (A) | Ranibizumab 0,5 mg | 2015 | Prospective | Large RCT | AntiVEGF | Ranibizumab | TAE | 6,800 | 0,781 | 0,610 | 5,270 | 8,330 | 8,709 | 0,000 | 125 | 1,09 | -0,31 |
| Mitchell et al. (RESTORE) | Ranibizumab 0,5 mg | 2011 | Prospective | Large RCT | AntiVEGF | Ranibizumab | PRN | 6,800 | 0,771 | 0,594 | 5,290 | 8,310 | 8,824 | 0,000 | 116 | 1,09 | -0,31 |
| Hernández-Bel et al. | Aflibercept 2 mg | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Aflibercept | FIX | 12,700 | 0,757 | 0,573 | 11,216 | 14,184 | 16,771 | 0,000 | 15 | 1,09 | 1,08 |
| Bhandari et al. (1) | Aflibercept 2 mg | 2019 | Retrospective | Real-life/Observational | AntiVEGF | Aflibercept | FIX | 5,400 | 0,663 | 0,440 | 4,100 | 6,700 | 8,143 | 0,000 | 167 | 1,10 | -0,65 |
| Bhandari et al. (1) | Ranibizumab 0,5 mg | 2019 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | FIX | 3,300 | 0,714 | 0,510 | 1,900 | 4,700 | 4,620 | 0,000 | 136 | 1,09 | -1,14 |
| Brown et al. (RIDE+RISE) | Ranibizumab 0,3 mg | 2013 | Prospective | Large RCT | AntiVEGF | Ranibizumab | FIX | 11,700 | 0,686 | 0,471 | 10,356 | 13,044 | 17,056 | 0,000 | 250 | 1,09 | 0,85 |
| Brown et al. (RIDE+RISE) | Ranibizumab 0,5 mg | 2013 | Prospective | Large RCT | AntiVEGF | Ranibizumab | FIX | 12,000 | 0,644 | 0,414 | 10,739 | 13,261 | 18,645 | 0,000 | 252 | 1,10 | 0,92 |
| Wells et al. (PROTOCOL T) | Aflibercept 2,0 mg | 2015 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 13,400 | 0,598 | 0,358 | 12,228 | 14,572 | 22,406 | 0,000 | 208 | 1,10 | 1,25 |
| Wells et al. (PROTOCOL T) | Bevacizumab 1,25 mg | 2015 | Prospective | Large RCT | AntiVEGF | Bevacizumab | FIX | 9,400 | 0,671 | 0,450 | 8,085 | 10,715 | 14,012 | 0,000 | 206 | 1,09 | 0,30 |
| Wells et al. (PROTOCOL T) | Ranibizumab 0,3 mg | 2015 | Prospective | Large RCT | AntiVEGF | Ranibizumab | FIX | 11,200 | 0,599 | 0,359 | 10,026 | 12,374 | 18,696 | 0,000 | 206 | 1,10 | 0,73 |
| Ishibashi et al. (REVEAL) | Ranibizumab 0,5 mg | 2015 | Prospective | Large RCT | AntiVEGF | Ranibizumab | FIX | 6,600 | 0,666 | 0,443 | 5,295 | 7,905 | 9,911 | 0,000 | 133 | 1,10 | -0,36 |
| Chatziralli et al. | Ranibizumab 0,5 mg | 2017 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 8,000 | 0,665 | 0,442 | 6,697 | 9,303 | 12,038 | 0,000 | 312 | 1,10 | -0,03 |
| Iglicki et al. | Dexamethasone implant (0,7 mg) | 2018 | Retrospective | Real-life/Observational | Steroid | Dex implant | PRN | 11,500 | 0,653 | 0,426 | 10,221 | 12,779 | 17,618 | 0,000 | 71 | 1,10 | 0,80 |
| Ciulla et al. | Aflibercept 2,0 mg | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Aflibercept | PRN | 5,500 | 0,613 | 0,375 | 4,299 | 6,701 | 8,978 | 0,000 | 1379 | 1,10 | -0,63 |
| Ciulla et al. | Bevacizumab 1,25 mg | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Bevacizumab | PRN | 5,500 | 0,536 | 0,287 | 4,450 | 6,550 | 10,267 | 0,000 | 3109 | 1,10 | -0,63 |
| Ciulla et al. | Ranibizumab 0,3 mg | 2018 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | PRN | 4,000 | 0,587 | 0,344 | 2,850 | 5,150 | 6,819 | 0,000 | 1352 | 1,10 | -0,98 |
| Callanan et al. (A) | Dexamethasone implant (0,7 mg) | 2016 | Prospective | Large RCT | Steroid | Dex implant | FIX | 4,340 | 0,571 | 0,327 | 3,220 | 5,460 | 7,595 | 0,000 | 165 | 1,10 | -0,90 |
| Callanan et al. | Dexamethasone implant (0,7 mg) | 2016 | Prospective | Large RCT | Steroid | Dex implant | FIX | 4,340 | 0,571 | 0,327 | 3,220 | 5,460 | 7,595 | 0,000 | 165 | 1,10 | -0,90 |
| Callanan et al. | Ranibizumab 0,5 mg | 2016 | Prospective | Large RCT | AntiVEGF | Ranibizumab | PRN | 7,600 | 0,523 | 0,274 | 6,575 | 8,625 | 14,528 | 0,000 | 166 | 1,11 | -0,13 |
| Matsuda et al. | Bevacizumab 1,25 mg | 2013 | Retrospective | Real-life/Observational | AntiVEGF | Bevacizumab | PRN | 6,300 | 0,533 | 0,284 | 5,256 | 7,344 | 11,828 | 0,000 | 124 | 1,11 | -0,44 |
| Callanan et al. (B) | Ranibizumab 0,5 mg | 2016 | Prospective | Large RCT | AntiVEGF | Ranibizumab | FIX | 7,600 | 0,523 | 0,274 | 6,575 | 8,625 | 14,528 | 0,000 | 166 | 1,11 | -0,13 |
| Li et al. | Ranibizumab 0,5 mg | 2019 | Prospective | Large RCT | AntiVEGF | Ranibizumab | PRN | 7,800 | 0,522 | 0,273 | 6,777 | 8,823 | 14,941 | 0,000 | 279 | 1,11 | -0,08 |
| Ozsayglii et al. | Aflibercept 2,0 mg | 2019 | Prospective | Large RCT | AntiVEGF | Aflibercept | PRN | 9,300 | 0,315 | 0,099 | 8,683 | 9,917 | 29,545 | 0,000 | 50 | 1,12 | 0,28 |
| Ozsayglii et al. | Dexamethasone implant (0,7 mg) | 2019 | Prospective | Large RCT | Steroid | Dex implant | PRN | 6,400 | 0,517 | 0,267 | 5,387 | 7,413 | 12,378 | 0,000 | 48 | 1,11 | -0,41 |
| Rajesh et al. | Dexamethasone implant (0,7 mg) | 2019 | Retrospective | Real-life/Observational | Steroid | Dex implant | PRN | 1,000 | 0,394 | 0,155 | 0,228 | 1,772 | 2,538 | 0,011 | 1434 | 1,11 | -1,71 |
| Boyer et al. (MEAD) | Dexamethasone implant (0,7 mg) | 2014 | Prospective | Large RCT | Steroid | Dex implant | PRN | 3,500 | 0,382 | 0,146 | 2,751 | 4,249 | 9,159 | 0,000 | 292 | 1,11 | -1,11 |
| Garweg et al. | Aflibercept 2 mg | 2019 | Prospective | Large RCT | AntiVEGF | Aflibercept | FIX | 10,000 | 0,378 | 0,143 | 9,259 | 10,741 | 26,458 | 0,000 | 529 | 1,11 | 0,45 |
| Sobaci et al. | Bevacizumab 1,25 mg | 2011 | Prospective | Real-life/Observational | AntiVEGF | Bevacizumab | PRN | 0,500 | 0,362 | 0,131 | -0,210 | 1,210 | 1,380 | 0,168 | 42 | 1,11 | -1,83 |
| Glassman et al. | Aflibercept 2 mg | 2020 | Retrospective | Large RCT | AntiVEGF | Aflibercept | PRN | 2,100 | 0,345 | 0,119 | 1,424 | 2,776 | 6,086 | 0,000 | 210 | 1,12 | -1,44 |
| Bilgic et al. | Dexamethasone implant (0,7 mg) | 2019 | Prospective | Real-life/Observational | Steroid | Dex implant | PRN | 13,500 | 0,300 | 0,090 | 12,912 | 14,088 | 45,033 | 0,000 | 153 | 1,12 | 1,29 |
| Baker et al. | Aflibercept 2 mg | 2019 | Prospective | Large RCT | AntiVEGF | Aflibercept | PRN | 2,200 | 0,267 | 0,071 | 1,677 | 2,723 | 8,245 | 0,000 | 210 | 1,12 | -1,42 |
| Ciulla et al. (1) | Ranibizumab 0.5 mg | 2020 | Retrospective | Real-life/Observational | AntiVEGF | Ranibizumab | Blank | 3,400 | 1,033 | 1,067 | 1,376 | 5,424 | 3,292 | 0,001 | 6926 | 1,06 | -1,10 |
| Ciulla et al. (2) | Aflibercept 2 mg | 2020 | Retrospective | Real-life/Observational | AntiVEGF | Aflibercept | Blank | 4,300 | 1,306 | 1,706 | 1,740 | 6,860 | 3,292 | 0,001 | 6459 | 1,02 | -0,88 |
| Ciulla et al. (3) | Bevacizumab 1,25 mg | 2020 | Retrospective | Real-life/Observational | AntiVEGF | Bevacizumab | Blank | 4,500 | 1,367 | 1,870 | 1,820 | 7,180 | 3,291 | 0,001 | 15273 | 1,01 | -0,83 |
| | | | | | | | | 8,130 | 0,443 | 0,197 | 7,261 | 8,999 | 18,339 | 0,000 | | | |